Vancouver, BC – The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and MRM Proteomics are collaborating to bring new diagnostic blood tests which will help clinicians manage patients with heart, lung and kidney disease more effectively.
The PROOF Centre – a not-for-profit organization focused on developing blood tests for chronic organ disease – and MRM Proteomics, a contract research organization, are integrating their expertise to create an end-to-end solution that uses protein signatures in the blood to predict the onset and progression of heart, lung, and kidney disease.
The PROOF Centre’s award-winning computational pipeline will be applied to guide the experimental design, and data quality control and analysis needed for the identification of protein signatures that can be used with other molecular signals to indicate heart, lung, and kidney disease. With its highly-skilled computation team of database specialists, clinical statisticians, bioinformaticians and computer and systems scientists, the PROOF Centre will support the analysis process from front-end experimental design to downstream statistical and biological analysis.
“This is a great way to begin to harness the strengths of the internationally-recognized computation capabilities that we’ve built up over the past few years,” says Dr. Bruce McManus, Director of the PROOF Centre. “Through this collaboration, MRM Proteomics’ expertise and leading technology will help us bring these tests to the clinic faster, ultimately helping improve patient care and lower heath costs.”
MRM Proteomics specializes in the absolute quantification of proteins in complex biological fluids such as blood and urine using Multiple Reaction Monitoring -Mass Spectrometry (MRM-MS). Their PeptiQuant™ MRM assays allow for the absolute quantification of hundreds of proteins at a time with unparalleled specificity and sensitivity, from a single drop of blood. These services lead to faster results for lower costs and sample volumes than other protein biomarker quantification methods.
“Our organizations’ offerings are clearly complementary in the field of protein biomarker discovery and validation.” said Andrew Munk, President and CEO of MRM Proteomics. “The discovery, validation and implementation of biosignatures are complex processes. Partnering with the PROOF Centre will provide our customers with access to the PROOF Centre’s internationally recognised computational tools and capabilities to optimize the design and analysis of their mass spec based proteomic biomarker studies.”